New StemSelect Library I From EMD Chemicals Gives Researchers Access to Cutting-Edge Discovery

GIBBSTOWN, N.J.--(BUSINESS WIRE)-- EMD Chemicals Inc. (“EMD”) a manufacturer of high-quality inhibitors, biochemicals, antibodies, proteins and kits, announces the launch of StemSelect™ Small Molecule Regulators 384-Well Library I as part of a continuing endeavor to offer convenient and reliable products to life science researchers.

Provided in a convenient 384-well format, the StemSelect™ Library I is an expert selection of 303 pharmacologically active, cell‑permeable (or cell receptor binding) InSolution™ modulators, many of which act in a reversible manner. The library consists primarily of inducers, activators, agonists, antagonists and other related compounds that are shown to modulate cell fate; making it suitable for a variety of studies, including examination of cellular survival, migration, proliferation, invasion, differentiation, signaling pathway analysis and fate determination.

“This library was developed to provide researchers with access to tools for cutting-edge discovery. It is a continuation of our expansion of stem-cell-research-related product offerings and a commitment to innovate the Calbiochem® brand product portfolio,” states Christina Shasserre, General Manager, EMD Global Biosciences.

Each library is supported with expert technical support and comprehensive documentation, including an SDF file that is provided in a CD with each package. Importantly, stringent stability and HPLC-purity testing on every batch of plates is conducted to ensure reliable results -- the first time and every time.

For more information regarding StemSelect™ Small Molecule Regulators 384-Well Library I or to download comprehensive documentation on the compounds included in each library, visit www.emdbiosciences.com/stemcells.

About EMD Chemicals Inc.

EMD Chemicals represents the North American chemical sector of Merck KGaA, Darmstadt, Germany. It is an international organization with approximately 800 employees and revenues of more than $US 350 million in 2009, providing specialty chemicals for pharmaceutical, biotech, cosmetic, automotive, plastics and other industrial applications. With headquarters in Gibbstown, N.J., EMD Chemicals is also engaged in the development, manufacture and distribution of a broad array of reagents used for life science research. Its sister company, EMD Crop BioScience located in Milwaukee, Wis., specializes in plant growth enhancement products for agricultural applications, including Optimize®. EMD Chemicals is known in the market by its product brands including Iriodin®, Xirallic®, Rona®, Calbiochem®, Novabiochem® and Novagen®, among others.

About Merck KGaA

Merck is a global pharmaceutical and chemical company with total revenues of € 7.7 billion in 2009, a history that began in 1668, and a future shaped by approximately 33,000 employees in 61 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merck.de/subscribe to register online, change your selection or discontinue this service.



CONTACT:

EMD Chemicals Inc.
Maziar Younessian, +1-858-450-5653
[email protected]

KEYWORDS:   United States  Europe  Asia Pacific  North America  Central America  South America  Canada  New Jersey

INDUSTRY KEYWORDS:   Health  Biotechnology  Medical Devices  Pharmaceutical  Manufacturing  Chemicals/Plastics  Medical Supplies

MEDIA:

Logo
 Logo

Suggested Articles

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.

The report features testimony that some NHS bodies are “actively instructed not to deal with industry by their local leadership.”